Zujian Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zujian Xiong has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Gary Kohanbash
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
54 shared publications - Itay Raphael
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
54 shared publications - Baoli Hu
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
53 shared publications - Ian F. Pollack
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
53 shared publications - Sameer Agnihotri
Department of Neurological Surgery, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania
53 shared publications - Dhivyaa Rajasundaram
Department of Pediatrics, University of Pittsburgh, PA, United States
52 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Wiley in iMetaOmics
Artificial intelligence‐driven bioinformatics: From analytical pipelines to model‐centered biological discovery
Traditional bioinformatic pipelines, which focus on predefined statistical analyses, are increasingly inadequate for handling high‐dimensional, heterogeneous, and context‐rich multi‐omics, spatial, and clinical datasets. Artificial intelligence (AI) is extending modern bioinformatics from predefined analytical pipelines toward learned biological representations, intervention‐oriented modeling, and more automated discovery workflows. This review comprehensively summarizes AI advances across genomic interpretation, single‐cell and spatial transcriptomics, multi‐omics integration, structural bioinformatics, disease stratification, precision medicine, and drug discovery. We categorize underlying AI technologies, including classical machine learning, deep representation learning, generative foundation models, and executable AI agents, and highlight their complementary use cases alongside inherent limitations and failure modes. Building on rather than claiming priority for the model‐centered paradigm described in recent literature, this review contributes a cross‐domain, failure‐aware evaluation framework organized around six unified axes: representation validity, task‐specific incremental value, robustness under biological and technical distribution shift, causal support, resource requirements, and validation/governance readiness. We further discuss key technical and social barriers and hierarchically prioritize future research directions. We conclude that AI complements rather than replaces conventional bioinformatic tools, extending the capacity for hypothesis generation and mechanism‐driven validation. This review provides structured and practical guidance for robust, interpretable, and clinically translatable AI‐driven biological discovery.
- 7 November 2026
- Published by Wiley in iMetaOmics
Open AccessArtificial intelligence‐driven bioinformatics: From analytical pipelines to model‐centered biological discovery
Traditional bioinformatic pipelines, which focus on predefined statistical analyses, are increasingly inadequate for handling high‐dimensional, heterogeneous, and context‐rich multi‐omics, spatial, and clinical datasets. Artificial intelligence (AI) is extending modern bioinformatics from predefined analytical pipelines toward learned biological representations, intervention‐oriented modeling, and more automated discovery workflows. This review comprehensively summarizes AI advances across genomic interpretation, single‐cell and spatial transcriptomics, multi‐omics integration, structural bioinformatics, disease stratification, precision medicine, and drug discovery. We categorize underlying AI technologies, including classical machine learning, deep representation learning, generative foundation models, and executable AI agents, and highlight their complementary use cases alongside inherent limitations and failure modes. Building on rather than claiming priority for the model‐centered paradigm described in recent literature, this review contributes a cross‐domain, failure‐aware evaluation framework organized around six unified axes: representation validity, task‐specific incremental value, robustness under biological and technical distribution shift, causal support, resource requirements, and validation/governance readiness. We further discuss key technical and social barriers and hierarchically prioritize future research directions. We conclude that AI complements rather than replaces conventional bioinformatic tools, extending the capacity for hypothesis generation and mechanism‐driven validation. This review provides structured and practical guidance for robust, interpretable, and clinically translatable AI‐driven biological discovery.
- Open Access
- 23 December 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (1) , 94-113
C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma
Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and a dismal prognosis. While immunotherapy has shown promise in treating some solid tumors, the treatment of GBM has been mostly unsuccessful because of a lack of targetable tumor antigens and high tumor heterogeneity. Here, we report RCAN1-4 as a novel tumor antigen derived from alternative splicing induced by the transcription factor C/EBPβ. Both C/EBPβ and RCAN1-4 are highly expressed in GBM and glioma stem cells as mesenchymal subtype hallmarks. We report an immunogenic HLA-A24-specific splicing junction epitope within exon 4 and exon 5 that is unique to RCAN1-4. This epitope was validated for its ability to stimulate T cell responses in HLA-A24 + donors and GBM patients, leading us to identify RCAN1-4-reactive T cell receptors (TCRs) for the construction of TCR-engineered T cells (TCR-T cells). Functional studies of TCR-Ts demonstrated the in vitro and in vivo killing of RCAN1-4 pos GBM tumor cells, highlighting its potential as an immunotherapeutic target in mesenchymal GBM.
- 23 December 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (1) , 94-113
Open AccessC/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma
Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and a dismal prognosis. While immunotherapy has shown promise in treating some solid tumors, the treatment of GBM has been mostly unsuccessful because of a lack of targetable tumor antigens and high tumor heterogeneity. Here, we report RCAN1-4 as a novel tumor antigen derived from alternative splicing induced by the transcription factor C/EBPβ. Both C/EBPβ and RCAN1-4 are highly expressed in GBM and glioma stem cells as mesenchymal subtype hallmarks. We report an immunogenic HLA-A24-specific splicing junction epitope within exon 4 and exon 5 that is unique to RCAN1-4. This epitope was validated for its ability to stimulate T cell responses in HLA-A24 + donors and GBM patients, leading us to identify RCAN1-4-reactive T cell receptors (TCRs) for the construction of TCR-engineered T cells (TCR-T cells). Functional studies of TCR-Ts demonstrated the in vitro and in vivo killing of RCAN1-4 pos GBM tumor cells, highlighting its potential as an immunotherapeutic target in mesenchymal GBM.
- 19 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (790) , eadp0675
The T cell receptor landscape of childhood brain tumors
The diverse T cell receptor (TCR) repertoire confers the ability to recognize an almost unlimited array of antigens. Characterization of antigen specificity of tumor-infiltrating lymphocytes (TILs) is key for understanding antitumor immunity and for guiding the development of effective immunotherapies. Here, we report a large-scale comprehensive examination of the TCR landscape of TILs across the spectrum of pediatric brain tumors, the leading cause of cancer-related mortality in children. We show that a T cell clonality index can inform patient prognosis, where more clonality is associated with more favorable outcomes. Moreover, TCR similarity groups’ assessment revealed patient clusters with defined human leukocyte antigen associations. Computational analysis of these clusters identified putative tumor antigens and peptides as targets for antitumor T cell immunity, which were functionally validated by T cell stimulation assays in vitro. Together, this study presents a framework for tumor antigen prediction based on in situ and in silico TIL TCR analyses. We propose that TCR-based investigations should inform tumor classification and precision immunotherapy development.
- 19 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (790) , eadp0675
The T cell receptor landscape of childhood brain tumors
The diverse T cell receptor (TCR) repertoire confers the ability to recognize an almost unlimited array of antigens. Characterization of antigen specificity of tumor-infiltrating lymphocytes (TILs) is key for understanding antitumor immunity and for guiding the development of effective immunotherapies. Here, we report a large-scale comprehensive examination of the TCR landscape of TILs across the spectrum of pediatric brain tumors, the leading cause of cancer-related mortality in children. We show that a T cell clonality index can inform patient prognosis, where more clonality is associated with more favorable outcomes. Moreover, TCR similarity groups’ assessment revealed patient clusters with defined human leukocyte antigen associations. Computational analysis of these clusters identified putative tumor antigens and peptides as targets for antitumor T cell immunity, which were functionally validated by T cell stimulation assays in vitro. Together, this study presents a framework for tumor antigen prediction based on in situ and in silico TIL TCR analyses. We propose that TCR-based investigations should inform tumor classification and precision immunotherapy development.
- Open Access
- 5 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104963
Glioblastoma vaccines: past, present, and opportunities
- 5 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104963
Open AccessGlioblastoma vaccines: past, present, and opportunities
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
Pearson's correlation coefficients analysis between immuno-PET signals and survival in ICI and control groups.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
Pearson's correlation coefficients analysis between immuno-PET signals and survival in ICI and control groups.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
MRI analysis of tumor volume before and after treatment.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
MRI analysis of tumor volume before and after treatment.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 validation by tissue staining.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 validation by tissue staining.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
SUV analysis and BioD data of CD69 immuno-PET.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
SUV analysis and BioD data of CD69 immuno-PET.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 is upregulated upon T-cell activation.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 is upregulated upon T-cell activation.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 analysis in single-cell RNA-seq data.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 analysis in single-cell RNA-seq data.